Multiple sclerosis is treated on three fronts: long-term medications that slow the disease itself, short courses of steroids to manage flare-ups, and therapies that target specific symptoms like fatigue, muscle stiffness, and bladder problems. There is no cure for MS, but treatment has advanced significantly, and most people with relapsing forms can now reduce their relapses by 50% or more with the right medication.
Disease-Modifying Therapies
The backbone of MS treatment is a class of drugs called disease-modifying therapies, or DMTs. These don’t fix existing damage, but they reduce how often the immune system attacks the protective coating around nerves in the brain and spinal cord. Starting a DMT early, ideally soon after diagnosis, gives you the best chance of slowing disability over time.
DMTs come in three forms. Injectable therapies are shots you give yourself at home on a schedule that ranges from daily to weekly. Oral therapies are pills taken at home, which are convenient but easy to forget. Infusion therapies are given through an IV at a medical facility, but appointments are spaced further apart, sometimes only every six months. The choice between them depends on how active your MS is, your tolerance for side effects, and what fits your life.
The majority of FDA-approved DMTs target relapsing-remitting MS, the most common form. If you have secondary progressive MS, where the disease has shifted from a relapse-and-recovery pattern to a steadier decline, several options exist. Siponimod (an oral tablet approved in 2019) and ofatumumab (a self-injection approved in 2020) are both approved for relapsing-remitting and secondary progressive forms. For primary progressive MS, which involves gradual worsening from the start without clear relapses, options are more limited. Ocrelizumab remains the main FDA-approved treatment shown to slow disability progression in primary progressive MS. In 2024, the FDA approved a subcutaneous (under-the-skin) version of ocrelizumab, giving patients an alternative to the standard IV infusion.
Treating Relapses
A relapse is a new or worsening neurological symptom that lasts at least 24 hours and isn’t caused by fever or infection. Common relapses include sudden vision problems, new numbness or tingling, or a noticeable increase in weakness. Not every relapse needs treatment. Mild ones sometimes resolve on their own over days to weeks.
When a relapse is severe enough to affect your daily function, the standard treatment is a short course of high-dose corticosteroids, typically given through an IV over three to five days. These don’t repair nerve damage, but they reduce inflammation quickly and can shorten the relapse. Some doctors follow up the IV treatment with a tapering course of oral steroids over several weeks to ease the transition off the medication. The steroids can cause temporary side effects like trouble sleeping, a metallic taste in the mouth, mood changes, and increased appetite.
For relapses that don’t respond to steroids, plasma exchange is sometimes used. This procedure filters the blood to remove the antibodies that are attacking the nervous system. It’s reserved for more severe situations and requires multiple sessions at a treatment center.
Managing Everyday Symptoms
MS produces a wide range of symptoms that DMTs don’t fully address. Muscle stiffness and spasms (spasticity) are among the most common. Baclofen, a muscle relaxant that acts on the central nervous system, is frequently prescribed to relieve cramping, tightness, and pain from spasticity. For spasticity concentrated in specific muscle groups, Botox injections can temporarily block the nerve signals causing the tightness, relaxing the targeted muscle for several months at a time. Botox is FDA-approved for both upper and lower limb spasticity in adults, and it’s also approved for bladder problems caused by MS, specifically urinary incontinence that hasn’t improved with other medications.
Fatigue is the single most reported MS symptom, affecting the vast majority of people with the disease. It’s a deep, persistent exhaustion that isn’t proportional to activity level. Treatment usually involves a combination of energy management strategies, regular exercise, and sometimes medication. Occupational therapists can help you restructure daily routines to preserve energy for the tasks that matter most.
Bladder dysfunction, pain, cognitive fog, and depression are also common and each has its own treatment pathway. The key point is that symptom management is a separate, ongoing conversation with your care team, running in parallel with whatever DMT you’re on.
Rehabilitation and Physical Therapy
Rehabilitation plays a significant role in maintaining function and quality of life with MS. Physical therapy focused on strength, balance, and gait can help preserve mobility as the disease progresses. Newer technologies are expanding what rehabilitation can do. Robot-assisted gait training helps people practice walking patterns with mechanical support. Virtual reality programs create interactive environments for balance and coordination exercises.
Transcranial magnetic stimulation, a technique that uses magnetic pulses to stimulate specific brain areas, has shown promise across multiple MS symptoms. Studies have found it can improve spasticity, reduce fatigue, sharpen cognitive function during task-oriented training, and even help regulate bladder activity. Another brain stimulation approach, transcranial direct current stimulation, has been shown to reduce chronic pain in MS patients and improve quality of life, with benefits that persist beyond the treatment sessions. These aren’t available everywhere yet, but they represent a growing toolkit beyond traditional physical therapy.
Stem Cell Transplantation
Hematopoietic stem cell transplantation, or HSCT, is an intensive treatment that essentially reboots the immune system. Your own stem cells are collected, your existing immune system is wiped out with chemotherapy, and then the stem cells are reinfused to rebuild a new immune system that, ideally, no longer attacks the nervous system.
The results can be striking. In clinical studies, 99% of people treated with HSCT had no relapses for one year, and 94% saw no worsening of disability over three years, compared to just 40% of those on standard drug treatments. But HSCT carries real risks, including infection during the period when the immune system is suppressed, and it requires weeks of recovery.
HSCT works best for people who are relatively early in their disease, still having relapses with active inflammation visible on MRI, and who haven’t yet accumulated significant disability. It’s most often considered for people whose MS remains active despite trying DMTs, or for those with very aggressive MS that’s progressing rapidly, such as two or more relapses in the past year. It is not typically offered to people with advanced disability or progressive MS without active inflammation.
The Role of Vitamin D
Low vitamin D levels are consistently linked to MS risk and disease activity, and most neurologists check vitamin D levels as part of routine MS care. The American Academy of Neurology’s MS subcommittee reviewed the evidence and recommended a wide range of supplementation doses, from 300 to 4,000 IU per day of vitamin D3, depending on your blood levels. If your levels are very low (below 10 ng/mL), your doctor may prescribe high-dose prescription vitamin D to bring levels up quickly before switching to a daily maintenance dose.
Vitamin D supplementation is not a substitute for DMTs, but maintaining adequate levels is considered a reasonable part of overall MS management. There are no strict universal guidelines yet, so the specific dose your neurologist recommends will depend on your bloodwork.
What’s Coming Next
Current DMTs work by targeting immune cells in the bloodstream, but they have limited ability to reach immune activity happening inside the brain itself. A new class of drugs called BTK inhibitors aims to change that. These small molecules can cross into the brain and quiet two key players: B cells (immune cells involved in the MS attack) and microglia (resident immune cells in the brain linked to the slow, smoldering progression that continues even when relapses stop).
Fenebrutinib, the furthest along in development, recently met its primary goals in two large Phase 3 trials. In people with primary progressive MS, it slowed disability progression at least as effectively as ocrelizumab over 120 weeks, with a benefit visible from week 24 onward. In people with relapsing MS, it significantly reduced the annual relapse rate compared to an existing oral therapy over at least 96 weeks. If approved, BTK inhibitors could be the first treatments to meaningfully address the progressive nerve damage that current drugs struggle to reach.